Lipid nanoparticle-mediated drug delivery to the brain

Adv Drug Deliv Rev. 2023 Jun:197:114861. doi: 10.1016/j.addr.2023.114861. Epub 2023 May 6.

Abstract

Lipid nanoparticles (LNPs) have revolutionized the field of drug delivery through their applications in siRNA delivery to the liver (Onpattro) and their use in the Pfizer-BioNTech and Moderna COVID-19 mRNA vaccines. While LNPs have been extensively studied for the delivery of RNA drugs to muscle and liver targets, their potential to deliver drugs to challenging tissue targets such as the brain remains underexplored. Multiple brain disorders currently lack safe and effective therapies and therefore repurposing LNPs could potentially be a game changer for improving drug delivery to cellular targets both at and across the blood-brain barrier (BBB). In this review, we will discuss (1) the rationale and factors involved in optimizing LNPs for brain delivery, (2) ionic liquid-coated LNPs as a potential approach for increasing LNP accumulation in the brain tissue and (3) considerations, open questions and potential opportunities in the development of LNPs for delivery to the brain.

Keywords: Blood-brain barrier; Ionic liquids; Ionizable cationic lipid; Lipid nanoparticles; Red blood cell hitchhiking.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Brain
  • COVID-19*
  • Humans
  • Lipids
  • Liposomes
  • Nanoparticles*
  • RNA, Small Interfering / genetics

Substances

  • Lipid Nanoparticles
  • Lipids
  • Liposomes
  • RNA, Small Interfering